Fulgent Genetics’ Post

Discover the leading companies driving innovations in bispecific antibodies with curated analytics by LARVOL CLIN. 🧬 Stay informed and ahead in the dynamic field of antibody therapeutics. Explore more here: https://bit.ly/4bFSDpD #BispecificAntibodies #LARVOLCLIN #BiotechLeaders #CancerData #Oncology

💡 Curious about growing your business with RxTROSPECT Oncology Analytics? Contact us to meet our co-founders, Mark Rutter and Dan Milberg, as they walk you through how to join our partner program. Visit https://lnkd.in/exFQszqz or email us at [email protected] #oncology #biotech #biotechnology #regulatoryaffairs #pharma #drugdevelopment #oncologytrials #oncologyresearch #cancer #oncology #regulatoryintelligence #consulting #lifesciences

Explore the top targets and the number of products in the bispecific antibody space with curated analytics by LARVOL CLIN. 🧬 Stay ahead with detailed insights into the evolving landscape of antibody therapeutics. Explore more here: https://bit.ly/4bFSDpD #BispecificAntibodies #LARVOLCLIN #BiotechInsights #CancerData #Oncology

Project Optimus is revolutionizing early oncology trials, aiming to ensure more effective and safer cancer drugs and improve patients' quality of life. Parexel experts have identified three strategies to help sponsors overcome challenges in achieving dose-optimization requirements. Here’s what we know works: 1️⃣ Design an integrated first-in-human study 2️⃣ Reach agreement with FDA at each step 3️⃣ Challenge guidelines with a compelling rationale Let me know your thoughts below and read more in our New Medicines, Novel Insights report! https://lnkd.in/eCJHXadb #ProjectOptimus #Oncology #ParexelBiotech #NovelInsights

Project Optimus is revolutionizing early oncology trials, aiming to ensure more effective and safer cancer drugs and improve patients' quality of life. Parexel experts have identified three strategies to help sponsors overcome challenges in achieving dose-optimization requirements. Here’s what we know works: 1️⃣ Design an integrated first-in-human study 2️⃣ Reach agreement with FDA at each step 3️⃣ Challenge guidelines with a compelling rationale Let me know your thoughts below and read more in our New Medicines, Novel Insights report! https://lnkd.in/giru-am2 #ProjectOptimus #Oncology #ParexelBiotech #NovelInsights

Project Optimus is revolutionizing early oncology trials, aiming to ensure more effective and safer cancer drugs and improve patients' quality of life. Parexel experts have identified three strategies to help sponsors overcome challenges in achieving dose-optimization requirements. Here’s what we know works: 1️⃣ Design an integrated first-in-human study 2️⃣ Reach agreement with FDA at each step 3️⃣ Challenge guidelines with a compelling rationale Let me know your thoughts below and read more in our New Medicines, Novel Insights report! https://lnkd.in/dUaBWFxM #ProjectOptimus #Oncology #ParexelBiotech #NovelInsights

Project Optimus is revolutionizing early oncology trials, aiming to ensure more effective and safer cancer drugs and improve patients' quality of life. Parexel experts have identified three strategies to help sponsors overcome challenges in achieving dose-optimization requirements. Here’s what we know works: 1️⃣ Design an integrated first-in-human study 2️⃣ Reach agreement with FDA at each step 3️⃣ Challenge guidelines with a compelling rationale Let me know your thoughts below and read more in our New Medicines, Novel Insights report! https://lnkd.in/effzmsp2 #ProjectOptimus #Oncology #ParexelBiotech #NovelInsights

Project Optimus is revolutionizing early oncology trials, aiming to ensure more effective and safer cancer drugs and improve patients' quality of life. Parexel experts have identified three strategies to help sponsors overcome challenges in achieving dose-optimization requirements. Here’s what we know works: 1️⃣ Design an integrated first-in-human study 2️⃣ Reach agreement with FDA at each step 3️⃣ Challenge guidelines with a compelling rationale Let me know your thoughts below and read more in our New Medicines, Novel Insights report! https://lnkd.in/estjE-Nc #ProjectOptimus #Oncology #ParexelBiotech #NovelInsights

Hear from IQVIA Biotech’s Global Head of Oncology Gerhard du Toit, together with Murray Aitken, executive director of the IQVIA Institute for Human Data Science as they address global oncology trends and how they stand to impact sponsors preparing for early and late phase oncology trials. Watch on-demand: https://bit.ly/4doNsw8 #oncology #biotech #oncologytrends #earlyphase #CancerResearch #ClinicalTrials #diversity #trialdesign